MDL Panel Combines Diabetes Drug Cancer Suits

Law360, New York (August 28, 2013, 3:38 PM EDT) -- The U.S. Judicial Panel on Multidistrict Litigation on Monday unified 53 suits over diabetes drugs marketed by Merck & Co. Inc., Novo Nordisk Inc., Eli Lilly & Co. and a Bristol-Myers Squibb Co. unit and purportedly linked to pancreatic cancer.

The panel created a new multidistrict case in the Southern District of California, saying that although it is typically hesitant to centralize litigation against multiple defendants who manufactured and marketed similar, competing products, the alleged cancer victims' claims were highly similar regardless of which company’s drugs...
To view the full article, register now.